Kidney transplant drug shows promise for proteinuria reduction
NCT ID NCT06165601
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether dapagliflozin, a diabetes drug, can reduce protein in the urine (proteinuria) in people who have had a kidney transplant and have chronic kidney disease. Researchers followed 55 patients for 6 months to see if the drug lowered protein levels and protected kidney function. The goal was to find a new way to slow kidney damage in transplant recipients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Montpellier
Montpellier, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new graft keep dialysis access working longer?
- Can a common gout pill shield hearts in kidney disease?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a new drug combo shield young hearts from transplant complications?